Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Feature

Research Reports
Quality Measure Concepts to Fill Gaps in Assessing Oral Oncolytic Adherence: A Multistakeholder Measurement Strategy
06/16/2022
Michael Reff, RPh, MBA
David Blaisdell, BA
Leigh Boehmer, PharmD
Sandra Kurtin, PhD
Shelley Fuld Nasso, MPP
Rachael Peroutky, MSPH
Katie Schultz, MSPH
Tom Valuck, MD, JD
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of oncology and quality measurement experts explored gaps in quality measures focused on oral oncolytic adherence and identified, prioritized, and refined measure concepts for further development.
A multistakeholder workgroup of...
06/16/2022
Journal of Clinical Pathways
From the Field
Real-world Utilization of Second-line Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy Versus Active Surveillance in Community Oncology Practice Patients With Advanced Ovarian Cancer
05/19/2022
Robert Reid, MD
Yiqiong Xie, PhD, MPH
Junxin Shi, PhD
Katrine L Wallace, PhD
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues analyzed second-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy in a real-world setting to understand how it is being utilized and the resultant impact on patients’ disease course.
Dr Wallace and colleagues...
05/19/2022
Journal of Clinical Pathways
From the Field
Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab
04/20/2022
Rouslan Kotchetkov, MD, PhD
David Susman
Erica DiMaria, MD
Lauren Gerard, MD
Derek Nay, MD
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues...
04/20/2022
Journal of Clinical Pathways

Advertisement

From the Field
Incidence and Cost of Radical Prostatectomy and Radiotherapy for NCCN Low-risk Prostate Cancer in Utah
03/16/2022
David Gill, MD
Jessica Baumgartner
Jesse Gygi
McKenzie Bell
Libby Petersen
Bryan Crawford
Zoya Sandhu
Brandon Barney, MD
Jonathan Tward, MD
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues analyzed rates of treatment for men with low-risk disease who were treated at either The Huntsman Cancer Institute or Intermountain Healthcare facilities, and modeled the costs associated with the presumptive...
David Gill, MD , and colleagues...
03/16/2022
Journal of Clinical Pathways
From the Field
Streamlining Institutional Pathway Processes: The Development and Implementation of a Pathology Molecular Consult to Facilitate Convenient and Efficient Ordering, Fulfillment, and Reporting for Tissue Molecular Tests
02/15/2022
Daniel Mettman, MD
Michael Goodman, MD
Joseph Modzelewski
Linda Verkruyse, MD
Susie Willis
Janet Barrett
Robert Hoyt, MD
Maryam Abdo, MBChB
Hanan Elsarraj, MD
Sharad Mathur, MD
Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...
Daniel Mettman, MD, and colleagues detail the work of two mid-sized VA medical centers in collectively developing and implementing a consult process as part of their oncology clinical pathways to standardize ordering, fulfillment, and...
Daniel Mettman, MD, and...
02/15/2022
Journal of Clinical Pathways
Research Reports
Factors Associated With Poor Outcomes in Patients who Receive Cancer Directed Therapy at the End of Life
02/15/2022
Yasmine Anouty, PharmD
Ila M. Saunders, PharmD, BCOP
Shanna Block, PharmD, BCOP
Katherine Medley, PharmD
Rabia S. Atayee, PharmD, BCPS
Megan Wall, MS
Alison Wall, MS
Carolyn Mulroney, MD
Janine Martino, PharmD, BCOP, APh
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and colleagues discern factors that may be associated with poor outcomes in adult patients who received intravenous cancer-directed therapy in the last 30 days of life.
Yasmine Anouty, PharmD, and...
02/15/2022
Journal of Clinical Pathways

Advertisement

Research Reports
Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer
12/15/2021
Helmy M Guirgis, MD, PhD
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed to examine cost of extended immune checkpoint inhibitor use beyond their indications in advanced/metastatic non-small cell lung cancer.
Helmy M Guirgis, MD, PhD, aimed...
12/15/2021
Journal of Clinical Pathways
Special Article
Recommendations for Enhancing the Value of Clinical Pathways: Findings From the 2020 Care Pathways Working Group
11/16/2021
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
Vasily Belozeroff, PhD
Experts identified concerns related to care pathways and their implementation that need to be addressed in order to promote high-quality pathways that offer utility in payer negotiation, reduce costs, and reduce unnecessary variation in care...
Experts identified concerns related to care pathways and their implementation that need to be addressed in order to promote high-quality pathways that offer utility in payer negotiation, reduce costs, and reduce unnecessary variation in care...
Experts identified concerns...
11/16/2021
Journal of Clinical Pathways
Research Reports
A Value-Based Collaborative Care Model by Payers, Providers, and Pharma
10/27/2021
Lili Brillstein, MPH
Donna Finale
Michael Udwin, MD
J Clin Pathways. 2021;7(7):22-29. doi:10.25270/jcp.2021.09.2 Received April 7, 2021; Accepted July 19, 2021.
J Clin Pathways. 2021;7(7):22-29. doi:10.25270/jcp.2021.09.2 Received April 7, 2021; Accepted July 19, 2021.
J Clin Pathways....
10/27/2021
Journal of Clinical Pathways

Advertisement

Research Reports
Potential Cost Effectiveness of FES-PET to Determine Estrogen Receptor Status in Metastatic Breast Cancer in the United States
10/20/2021
Poorni M. Manohar, MD
Hannah M. Linden, MD
Josh A. Roth, PhD, MHA
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al...
10/20/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use